Trials / Completed
CompletedNCT00960128
Observational Prospective Study on Patients Treated With Norditropin®
NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21,249 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.
Conditions
- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
- Adult Growth Hormone Deficiency
- Genetic Disorder
- Turner Syndrome
- Foetal Growth Problem
- Small for Gestational Age
- Chronic Kidney Disease
- Chronic Renal Insufficiency
- Noonan Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults. |
| DRUG | somatropin | The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children. |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2016-12-31
- Completion
- 2016-12-31
- First posted
- 2009-08-17
- Last updated
- 2017-10-12
Locations
23 sites across 23 countries: Argentina, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Lithuania, Luxembourg, Netherlands, Norway, Russia, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00960128. Inclusion in this directory is not an endorsement.